We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“For many years, we've functioned in a space where we thought there's not that much we can do for heart failure, and I would now argue stridently against that. You can see the incredibly low numbers needed to treat here. Only a handful of patients need to be exposed to these therapies to derive a significant benefit on mortality. These are data we should incorporate in our clinical practice without exclusion.”
“Amongst the many treatment recommendations in this guideline addressing care, the unambiguous nature of 'GDMT' emphasizes what works best and should be widely deployed.”
“From epidemiology through clinical presentation and therapeutics, medical and surgical, we have exercised every opportunity to make specific mention of issues related to HFpEF.”
No takes yet. Share an insight, caveat, or question.
Yancy et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: